Cabio Biotech (Wuhan) Second Quarter 2024 Earnings: EPS: CN¥0.26 (vs CN¥0.13 in 2Q 2023)
Cabio Biotech (Wuhan) (SHSE:688089) Second Quarter 2024 Results
Key Financial Results
- Revenue: CN¥143.8m (up 30% from 2Q 2023).
- Net income: CN¥43.6m (up 112% from 2Q 2023).
- Profit margin: 30% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue.
- EPS: CN¥0.26 (up from CN¥0.13 in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cabio Biotech (Wuhan) Earnings Insights
Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China.
Performance of the Chinese Chemicals industry.
The company's shares are down 1.8% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Cabio Biotech (Wuhan) that you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:688089
Cabio Biotech (Wuhan)
Develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers.
Excellent balance sheet with proven track record.